We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effects of Si-Miao-Yong-An decoction on myocardial I/R rats by regulating gut microbiota to inhibit LPS-induced TLR4/NF-κB signaling pathway.
- Authors
Cui, Yuting; Zhang, Fangyuan; Xu, Weiming; Li, Ziyun; Zou, Jiaxi; Gao, Ping; Hu, Jingqing
- Abstract
Background: Coronary Artery Disease (CAD) is primarily caused by inflammation which is closely linked to the gut microbiota. Si-Miao-Yong-An (SMYA) decoction is a traditional Chinese herbal formula with anti-inflammatory properties that found to be effective against CAD. However, it is still unclear whether SMYA can modulate gut microbiota and whether it contributes to the improvement of CAD by reducing inflammation and regulating the gut microbiota. Methods: The identification of components in the SMYA extract was conducted using the HPLC method. A total of four groups of SD rats were orally administered with SMYA for 28 days. The levels of inflammatory biomarkers and myocardial damage biomarkers were measured through ELISA, while echocardiography was used to assess heart function. Histological alterations in the myocardial and colonic tissues were examined following H&E staining. Western blotting was performed to evaluate protein expression, whereas alterations in gut microbiota were determined by 16 s rDNA sequencing. Results: SMYA was found to enhance cardiac function and decrease the expression of serum CK-MB and LDH. SMYA was also observed to inhibit the TLR4/NF-κB signaling pathway by downregulating the protein expression of myocardial TLR4, MyD88, and p-P65, leading to a reduction in serum pro-inflammatory factors. SMYA modified the composition of gut microbiota by decreasing the Firmicutes/Bacteroidetes ratio, modulating Prevotellaceae_Ga6A1 and Prevotellaceae_NK3B3 linked to the LPS/TLR4/NF-κB pathway, and increasing beneficial microbiota such as Bacteroidetes, Alloprevotella, and other bacterial species. Moreover, SMYA was found to safeguard the intestinal mucosal and villi structures, elevate the expression of tight junction protein (ZO-1, occludin), and reduce intestinal permeability and inflammation. Conclusions: The results indicate that SMYA has the potential to modulate the gut microbiota and protect the intestinal barrier, thereby reducing the translocation of LPS into circulation. SMYA was also found to inhibit the LPS-induced TLR4/NF-κB signaling pathway, leading to a decrease in the release of inflammatory factors, which ultimately mitigated myocardial injury. Hence, SMYA holds promise as a therapeutic agent for the management of CAD.
- Subjects
ECHOCARDIOGRAPHY; STATISTICS; HERBAL medicine; HIGH performance liquid chromatography; MYOCARDIUM; STAINS &; staining (Microscopy); GUT microbiome; ANIMAL experimentation; WESTERN immunoblotting; ONE-way analysis of variance; NF-kappa B; CELL receptors; HEALTH outcome assessment; CELLULAR signal transduction; RATS; T-test (Statistics); CORONARY artery disease; ENZYME-linked immunosorbent assay; ASPIRIN; DESCRIPTIVE statistics; RESEARCH funding; PLANT extracts; DATA analysis software; DATA analysis; STATISTICAL correlation; CHINESE medicine
- Publication
BMC Complementary Medicine & Therapies, 2023, Vol 23, Issue 1, p1
- ISSN
2662-7671
- Publication type
Article
- DOI
10.1186/s12906-023-04013-9